Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV
Li G, Park LS, Lodi S, Logan RW, Cartwright EJ, Aoun-Barakat L, Casas JP, Dickerman BA, Rentsch CT, Justice AC, Hernán MA. Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV. AIDS 2022, 36: 1689-1696. PMID: 35848570, PMCID: PMC9444875, DOI: 10.1097/qad.0000000000003314.Peer-Reviewed Original ResearchConceptsTDF/FTCTenofovir disoproxil fumarateCoronavirus disease 2019 (COVID-19) outcomesTAF/FTCAntiretroviral therapyTenofovir alafenamideDisoproxil fumarateRisk ratioAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionCOVID-19 ICU admissionsIntensive care unit admissionPrevious COVID-19 diagnosisSyndrome coronavirus 2 infectionCOVID-19-related hospitalizationVeterans Aging Cohort StudySARS-CoV-2 infectionCare unit admissionCoronavirus 2 infectionChronic kidney diseaseHIV viral loadGlomerular filtration rateAging Cohort StudyCorresponding risk ratioPooled logistic regression